Results 211 to 220 of about 547,025 (332)

Effectiveness and safety of baricitinib for juvenile idiopathic arthritis associated uveitis or chronic anterior antinuclear antibody positive uveitis

open access: yesArthritis Care &Research, Accepted Article.
Objectives Evaluate the efficacy and safety of baricitinib in paediatric patients with active JIA‐U or chronic anterior ANA‐positive uveitis, who had an inadequate response to MTX or bDMARDs. Methods JUVE‐BRIGHT was an open‐label, active‐controlled, Phase‐3 multicentre trial which utilized a novel design, including 1:1 randomization to an active ...
Athimalaipet V. Ramanan   +7 more
wiley   +1 more source

Genomic characteristics and genetic manipulation of the marine yeast Scheffersomyces spartinae. [PDF]

open access: yesAppl Microbiol Biotechnol
Sharma A   +7 more
europepmc   +1 more source

Testing A Personalized Approach to Chronic Low Back Pain: A Randomized Controlled Trial in Older Veterans

open access: yesArthritis Care &Research, Accepted Article.
Objective We aimed to test the efficacy of personalized treatment of older Veterans with chronic low back pain (CLBP) delivered by Aging Back Clinics (ABC) as compared with usual care (UC). Methods Two hundred ninety‐nine Veterans age 65‐89 with CLBP from 3 VA medical centers underwent baseline testing, randomization to ABC or UC and 12 months follow ...
Debra K. Weiner   +9 more
wiley   +1 more source

The HTIRDB: A resource containing a transcriptional atlas for 105 different tissues from each of seven species of domestic herbivore

open access: yesiMeta
Luoyang Ding   +35 more
doaj   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

open access: yesArthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy